Garlic in Hyperlipidemia Caused by HAART
|ClinicalTrials.gov Identifier: NCT00029250|
Recruitment Status : Withdrawn
First Posted : January 10, 2002
Last Update Posted : March 22, 2013
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections Hypercholesterolemia Hypertriglyceridemia Hyperglycemia||Drug: Garlic powder standardized to allicin||Phase 2|
Clinical evaluation of garlic in HIV disease is warranted for several reasons. First, garlic is used as a botanical medicine and as an alternative therapy by many HIV-infected individuals. Baseline data from the Bastyr's Alternative Medicine Care Outcomes in AIDS (AMCOA) study  indicate that garlic is the most frequently used botanical medicine among HIV-infected men and women (52.9%) who utilize complementary and alternative medicine (CAM). In the same cohort, 50% of the subjects who use antiretroviral therapy are also taking garlic supplements. Second, there is a growing body of studies that indicate that garlic exhibits lipid and glucose lowering as well as hepato-protective activities. Third, several of the pharmacological activities of garlic and their reported clinical benefits in other conditions, especially in hyperlipidemia, may be relevant in the management of highly active antiretroviral therapy (HAART) in HIV-infected subjects.
Study Medication: We will utilize GarlicinTM, an allicin-standardized dried garlic supplement in two escalating doses in HIV-infected subjects who are receiving HAART.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase II, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study on the Effects of Garlic on Hyperlipidemia Induced by HAART in HIV-positive Individuals|
|Study Start Date :||November 2001|
|Actual Primary Completion Date :||May 2003|
|Actual Study Completion Date :||May 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029250
|United States, Washington|
|Bastyr University Center for Natural Health|
|Seattle, Washington, United States, 98103|
|University of Washington Harborview Medical Center|
|Seattle, Washington, United States, 98104|
|Principal Investigator:||Leanna J Standish, ND, PhD||Bastyr University|